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Abstract:
BACKGROUND & AIMS: Patients with systemic sclerosis (SSc) have impairments in
gastrointestinal smooth muscle function. The disorder has been associated with circulating
antibodies to cholinergic muscarinic type-3 receptor (M3-R). We investigated whether it is
possible to neutralize these antibodies with pooled human immunoglobulin (Ig)Gs (pooledhIgG).
METHODS: We studied the effects of IgGs purified from patients with SSc (SScIgGs) on
cholinergic nerve stimulation in rat colon tissues. We also examined the effects of SScIgGs on
M3-R activation by bethanechol (BeCh), M3-R occupancy, and receptor binding using
mmunofluorescence, immunoblot, and ELISA analyses of human internal anal sphincter (IAS)
smooth muscle cells (hSMCs), before and after administration of pooledhIgG. Functional
displacement of M3-R occupancy by the SScIgGs was compared with that of other IgGs during
the sustained phase of BeCh-induced contraction of intact smooth muscles from rats.
RESULTS: SScIgG significantly attenuated neutrally mediated contraction and acetylcholine
release in rat colon as well as BeCh-induced sustained contraction of the IAS smooth muscle. In
immunofluorescence analysis, SScIgG co-localized with M3-R. In immunoblot and ELISA
analyses, M3-R loop-2 peptide and human IAS SMC membrane lysates bound significant
amounts of SScIgG, compared with IgGs from healthy individuals and pooledhIgG. Binding was
significantly attenuated by application of pooledhIgG, which by itself had no significant effect.
Incubation of samples with pooledhIgG, or mixing pooledhIgG with SScIgG before
administration to tissues, significantly reduced binding of SScIgG, indicating that pooledhIgG
prevents SScIgG blockade of M3-R.
CONCLUSIONS: In studies of rat and human tissues, pooled human IgGs prevent and reverse
the cholinergic dysfunctions associated with the progressive gastrointestinal manifestations of
SSc, by neutralizing functional M3-R antibodies present in the circulation of patients with SSc.
Keywords: connective tissue disease; smooth muscle atrophy, fibrosis, animal model, antibody
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Introduction
Scleroderma or systemic sclerosis (SSc) is a progressive autoimmune connective tissue
disease associated with progressive fibrosis of skin and numerous internal organs.1 The
gastrointestinal (GI) tract is the most common internal organ system affected in SSc with as
many as 90% of the patients developing esophageal

symptoms.2,3 Interestingly, a large

percentage of SSc patients display involvement of the anorectum, causing alterations of the
IAS function and frequent fecal incontinence.4-6
GI dysmotility in SSc is believed to be neuropathic in origin, with subsequent smooth muscle
atrophy and fibrosis.2 The early stages may involve neuropathic changes in the cholinergic
innervation, and in the latter stages there are myopathic changes.2,7 Following earlier studies by
Bacman and colleagues on the presence of circulating M3-R in patients with Sjögren’s
syndrome,8 Goldblatt et al.9 demonstrated the presence of such antibodies in SSc patients. These
antibodies caused significant dysfunction in the mouse colonic smooth muscle contraction
induced by the M3-R agonist, carbachol.

These studies suggested that neuropathic

gastrointestinal dysfunction caused by circulating antibody interference with cholinergic
innervation was responsible for GI dysmotility in SSc. Our recent studies using isolated SMCs
of the rat IAS demonstrated that SScIgGs cause ~50% inhibition of M3-R activation and
suggested that this mechanism in part is responsible for the GI smooth muscle myopathy in
SSc.10 None of the above studies, however, neither examined the status of the actual cholinergic
innervation and its effects in human SMCs, nor investigated the possible reversal of SScIgGs’
effects.
Because of the lack of clear understanding of the SSc pathophysiological mechanism/s,
there is no effective disease modifying treatment for SSc. Pooled human IgG (pooledhIgG)
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also known as intravenous immunoglobulin (IVIG) has been clinically employed as a potent
immunomodulating agent in various immune-mediated disorders.11-13 The use of pooledhIgG
for the treatment of SSc has been supported by studies in the tight skin (TSK) animal model of
SSc demonstrating that pooledhIgG may cause beneficial effects14 either by counteracting
antifibroblast antibodies or decreasing expression of the type I collagen gene,15 as well as by
modulating the secretion of profibrotic cytokines TGFβ1 and IL-4.14,16 However, the exact
mechanisms of action of pooledhIgG in SSc are not known. Thus, owing to the potential
pathogenetic role of circulating antibodies in SSc-related GI dysmotility it will be important to
determine the effect of pooledhIgG in SSc in inhibition of the effect of SScIgGs against M3-R.
In the present study we determined the site of action of the M3-R autoantibodies present in
SScIgGs using rat colon to assess a cholinergic involvement, and then assessed the myopathic
changes using human IAS SMC and rat IAS smooth muscles. The studies also investigated the
role of pooledhIgG in reversing the cholinergic blockade by SScIgGs in these systems.

Materials and Methods
Isolation and Purification of IgGs from SSc Patients and Normal Volunteers
Six female patients with SSc fulfilling the criteria for SSc classification of the American
College of Rheumatology17 were studied. The studies were approved by the Institutional
Review Board of Thomas Jefferson University. Disease duration varied from 4 to 42 years. All
patients had typical esophageal manometric features and two had fecal incontinence.18 Total
IgGs were purified from plasma of the six SSc patients (SScIgGs) and two normal volunteers
(NIgGs), by use of recombinant protein G-Sepharose 4B conjugate (Zymed Laboratories, San
Francisco, CA) and disposable spin-out columns (G Biosciences, Maryland Heights, MO) as
published previously.19
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Human IAS Tissue Samples and SMCs Isolation
Human IAS smooth muscle tissue samples were obtained from five subjects who
underwent surgical removal of the anorectal region. SMCs from the circular smooth muscle
layer of the IAS were isolated as described previously.10 Isolated cells were resuspended in
DMEM growth medium with 5% fetal bovine serum and antibiotics on Lab-Tek II chamber
slides (Nulgene Nunc International, Naperville, IL) at 37°C and 5% CO2 in an incubator with
regulated humidity.

Experiments in Human SMCs
Effect of SScIgGs, NIgGs and PooledhIgG on Human IAS SMC Contraction
The SMCs isolated as described above were divided into different aliquots, and their
responses to bethanechol (BeCh; 10-9 to 10-4 M) before and after SScIgG, NIgG , pooledhIgG
(0.1 to 1 mg/ml) and the combination of either pooledhIgG and SScIgG or pooledhIgG and
NIgG (0.1 to 1 mg/ml each) for 10 min, were determined. In some experiments, we also
examined the effects of higher concentrations (10 mg/ml) of pooledhIgG. The cells were then
fixed with acrolein (final concentration 1%) and cell length was measured by using digital
micrometry.10 To determine the selectivity of action of the SScIgG on the M3-R activation by
BeCh, we compared the effects of different IgGs and their combinations on α1-adrenoceptor
(α1-AR) activation by phenylephrine (10-9 to 10-4 M), and K+-depolarization with KCl (2.5 mM
to 40 mM).
Immunofluorescence Analysis
The human IAS SMCs were quickly rinsed with Dulbecco's phosphate-buffered saline
(DPBS) and non specific antibody binding sites were blocked with 1% FBS in DPBS. To
determine the membrane binding efficiency of SScIgG, vs NIgG and pooledhIgG, SMCs were
incubated with 5 µg/ml of these antibodies for different time points (0 to 30 min) at 370C, and
fixed with acetone for 10 min at −20°C. The cells were then washed three times with DPBS
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and stained with the anti-human IgG-FITC-conjugated antibody as described previously.20
Cells were co-stained with 5µg/ml of anti-M3-R antibody, as an internal control to detect
colocalization of M3-R with SScIgG in human IAS SMCs. These cells were rinsed with DPBS
and stained with anti rabbit-TR-conjugated antibody. The cells were finally stained with
nuclear staining dye DAPI and images were taken employing a Nikon Eclipse 80i microscope
as described previously.20
Immunofluorescence Intensity (IFI) Calculation
IFI was calculated by using NIS Elements 3.1 software by two different methods as follow:
a). Intensity per unit area: For this purpose, 20 µm2 of cell membrane area was selected at four
different sites of the cell membrane and pixel intensity under this area was calculated and
plotted as a bar graph (Fig. 2B and E). The above procedure was repeated in 20 randomly
selected cells and calculated as means ± SE. b). Line graph method: For this purpose, intensity
under a line of 1-µm width across the cell avoiding the nucleus was calculated and plotted for
the membrane IFI of different IgGs (Fig. 3A). The Pearson’s colocalization coefficient was
determined for each cell and Mean ± SE was calculated and plotted (Fig. 3B).21
Western Blot (WB) Analyses for Interaction of SScIgGs vs. NIgGs and pooledhIgG with
M3-R
These studies were performed to determine the binding of SScIgG vs. NIgG, and
pooledhIgG to M3-R in human IAS SMC membrane fractions (HISMF) prepared following a
previously described method.22 The membrane protein was electrophoresed on 7.5% SDSPAGE and transferred to a PVDF membrane by using iBlot.7 The membrane was subdivided
into five equal parts that were kept in blocking buffer (5% bovine serum albumin in Tris buffer
saline pH 7.2) for 1 h. These membranes were separately incubated overnight at 4°C with 5
µg/ml of M3-R antibody, SScIgG, NIgG, pooledhIgG, and pooledhIgG+SScIgG, washed three
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times with TBS containing 0.1% Tween (TBST), and stained with corresponding HRPconjugated secondary antibodies. The membranes were washed three times for 10 min with
TBST, and stained with tertiary antibody against HRP (Chemi IR detection system from LICOR biosciences) for 1 h at RT in TBST containing 0.002% SDS. The membranes were
washed and scanned with a LI-COR Odyssey Imaging System infrared scanner, and relative
densities of M3-R and human IgGs were plotted using Image-J (NIH).10 Na+-K+ ATPase (a
membrane marker) antibody was used as a loading control.
Enzyme-Linked Immunosorbent Assay (ELISA)
To determine direct binding of SScIgG to the M3-R and its interaction with pooledhIgG in
the human IAS SMCs, we performed ELISA studies employing an ELISA kit (NB-E10632
from Novatein Biosciences, Inc., Cambridge, MA) using different concentrations of purified
M3-R peptide or HISMF according to the manufacturer’s instructions. These experiments
provided the optimal concentrations of M3-R peptide and the HISMF to determine the M3-R
binding.
To determine the M3-R binding, 400 µg/ml of HISMF and peptides corresponding to the
M3-R second extracellular loop-2 (M3-RL2; KRTVPPGECFIQFLSEPTITFGTAI, amino acids
213–237) and Loop-3 (M3-RL 3; NTFCDSCIPKTFWN, amino acids 514–527) at a
concentration of 400 pg/ml were separately dissolved in the carbonate buffer and adsorbed
onto separate multiwell plates used for ELISA.23 From 0 to 6 µg/ml of M3-R antibody, SScIgG,
NIG, pooledhIgG, and pooledhIgG+SScIgG were added to these multiwell plates and
incubated at 37oC for 1 h. Plates were washed three times with DPBST and incubated for 1 h at
RT with anti-rabbit-HRP-conjugated for M3-R antibody and anti-human-HRP-conjugated
secondary antibodies for SScIgG, NIgG, pooledhIgG and pooledhIgG+SScIgG and washed
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three times with DPBST and 100 µl of TMB substrate was added and kept for 15 min at RT.
Following substrate addition, 100 µl of Stop solution was added to each well and absorbance
was recorded at 450nm with ELISA reader.
Neutralization Studies
For this purpose 400 pg/ml M3-R peptide was adsorbed on multiwell plates (used for
ELISA) and the effect of pooledhIgG on the maximal binding of the SScIgG (5 µg/ml) to the
M3-R peptide was determined by ELISA. We substituted SScIgG alone with the mixture of
SScIgG+pooledhIgG (mixed at 37oC for 1h; pooledhIgG concentrations ranged from 0 to 15
µg/ml diluted in PBS). As a negative control for the pooledhIgG effects, we used inactivated
pooledhIgG (by proteinase digestion followed by boiling). The OD readings obtained using the
combination of pooledhIgG+SScIgG were compared with those of the maximal OD reading
obtained with M3-R peptide and SScIgG alone. To determine the neutralization of the M3-R
binding with the SScIgGs by pooledhIgG in the IAS SMC membrane, we followed the
procedure described above except for substitution of M3-RL2 with 400 µg/ml of HISMF.

Experiments using Intact Rat Colon and IAS Smooth Muscles: Smooth
Muscle Strips Preparation and Isometric Tension Recording
Cholinergic Nerve Stimulation Experiments
Male Sprague-Dawley rats (300–350 g) were euthanized by decapitation, and the lower
portion of the colon was surgically removed and transferred to oxygenated (95% O2 + 5% CO2)
Krebs physiological solution (KPS) at 37oC. The composition of KPS (in mM) was: 118.07
NaCl, 4.69 KCl, 2.52 CaCl2, 1.16 MgSO4, 1.01 NaH2PO4, 25 NaHCO3, and 11.10 glucose. The
colonic smooth muscle strips (~0.5x7 mm) from the circular smooth muscle layer were
prepared for the recording of isometric tension using 2 ml organ baths as described
previously.24,25 These smooth muscle strips were then transferred to 2 ml organ baths
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containing oxygenated KPS and allowed to equilibrate for 1-2 h. To determine the effects of
cholinergic nerve stimulation, electrical field stimulation (EFS; 10 V, 0.25 to 10 Hz, 4 sec
train, each pulse of 0.5 ms) was delivered using a Grass stimulator (model S88; Grass
Instruments Co., Quincy, MA). The EFS responses (percent maximal increase in the basal
activity) were quantified before and after tetrodotoxin (TTX; 10-6 M), atropine (10-7 M),
darifenacin (10-7 M), NIgG and SScIgG (1mg/ml), pooledhIgG (10 mg/ml), and pooledhIgG
(10mg/ml)+SScIgG (1mg/ml).
Acetylcholine (ACh) Measurements
Rat colonic smooth muscles were prepared for the EFS as described above. The muscle
bath perfusates were collected in the basal state, and following EFS before and after 0Ca2+,
TTX (10-6 M), and SScIgG (1mg/ml) before and after pooledhIgG. ACh measurements were
made using choline/acetylcholine Quantification kit (BioVision, Milpitas, CA) following
manufacturer’s instructions.

Data were quantified employing fluorometric (Fluorometer

Optima Micropipette Reader; BMG Labtech Ortenberg, Germany) analysis with MARS
software.
Functional Displacement of M3-R Experiments using Intact IAS Smooth Muscle
We examined the responses to SScIgG, NIgG and pooledhIgG (0.1 to 1 mg/ml) on the
sustained phase of IAS contraction by BeCh (10-4 M). These effects were compared with those
of M3-R antagonist darifenacin (10-9 M to 5x10-8 M). The basal tone in each smooth muscle
strip of the colon and IAS was determined at the end of each experiment by the administration
of EDTA (50 mM) and 0Ca2+.25,26 All experimental protocols were approved by the IACUC of
Thomas Jefferson University in accordance with the recommendations of the American
Association for the Accreditation of Laboratory Animal Care.

9
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Drugs and Chemicals
BeCh, KCl, phenylephrine, TTX, atropine, and M3-R antibody were purchased from Sigma
Aldrich (St. Louis, MO). PooledhIgG (IVIG) was a generous gift from PriviGen (King of
Prussia, PA). M3-R loop-2 (M3-RL2) and loop-3 (M3-RL3) peptides were from Peptide 2.0 Inc.
(Chantilly, VA), Darifenacin (M3-R selective antagonist) was a gift from Pfizer (Sandwich,
Kent, UK). Na+-K+ ATPase monoclonal antibody (a membrane marker) was from Santa Cruz
Biotech. (Santa Cruz, CA).
Statistical Analysis
Data are presented as means ± SE of multiple experiments. P values less than 0.05 were
considered statistically significant. The concentration-response curves were fitted by nonlinear
regression using the computer software Prism (GraphPad Software, San Diego, CA).

Results
Effect of SScIgGs on Cholinergic Nerve Stimulation in the Colon: Studies in Intact Rat
Colonic Smooth Muscles
EFS caused a frequency-dependent increase in the contraction of the colonic smooth
muscles, that was attenuated by TTX, atropine, and darifenacin (*; p<0.05; n=6; Fig. 1A),
suggesting that EFS causes contraction of the colonic smooth muscle via cholinergic nerve
stimulation, partly through M3-R activation. The data further showed that SScIgGs (in
contrast with pooledhIgG) caused significant suppression of the EFS-induced cholinergic
contraction (*; p<0.05; n=6). The latter effect was reversed by 10mg/ml pooledhIgG to the
level that was not significantly different from the control values (p>0.05; n=6).
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Effect of SScIgGs on EFS-Evoked ACh Release in Intact Rat Colonic Smooth Muscles
Direct measurements of ACh from myenteric neurons revealed that EFS causes a
significant increase in ACh release, which was significantly attenuated by 0Ca2+, TTX as well
as by SScIgG (**; p<0.05; Fig. 1B; n=4). A complete obliteration of the EFS-evoked release of
ACh by 0Ca2+ and TTX suggests definitive neurotransmitter release of ACh. The suppressant
effects of SScIgGs on ACh release were reversed by pooledhIgG (*; p<0.05; n=4), whereas
pooledhIgG by itself had no significant effects on basal release of ACh (p>0.05).
Effect of SScIgG vs. NIgG and PooledhIgG on BeCh-Induced Contraction of Human
IAS SMCs
SScIgGs significantly attenuated the contraction of BeCh-induced M3-R activation in
human IAS SMCs (*; p<0.05; n=6), and that inhibition was significantly reversed by
pretreatment of the SMC with 1mg/ml pooledhIgG (**; p<0.05). The maximal effective
concentration of BeCh (10-4 M), in control experiments induced a SMC contraction of 19.7 ±
1.5%. SScIgG (1mg/ml) significantly attenuated this response to 5.7

±

0.1% (~70%

inhibition; *; p<0.05; n=6), and pooledhIgG (10 mg/ml) reversed this to 18.6 ± 2.4%, a value
not significantly different from controls (p<0.05; n=6; Fig. 1C). In contrast, the contractile
effects of phenylephrine (alpha1-adrenoceptor or α1-AR activator) and K+ depolarization by
KCl were not modified by SScIgG (data not shown). These data demonstrate the selectivity of
the suppressant effects of SScIgG in the M3-R activation in the human IAS SMC.
M3-R Occupancy by SScIgGs vs. NIgGs and PooledhIgG in Human IAS SMC

Data showed that SScIgG binds to the SMCs with M3-R selective immunofluorescence
intensity (IFI) saturating at 20 min (IFI of M3-R using M3-R antibody was considered as 100
%; Fig. 2A,B). Significant IFI with SScIg was observed at 5 and 10 min as 79.57 ± 5.43 and
89.47 ± 6.24%, respectively (*; p<0.05; n=6). Therefore, a 10 min time frame was selected for
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the subsequent experiments with SScIgG. In contrast with the SScIgG, NIgG and pooledhIgG
(14 ± 1.5 and 16 ± 2.2%, respectively) had significantly less binding (*; p<0.05; Fig. 2C,D,E).
Collectively, these data reveal that SScIgG has significantly higher binding to the IAS SMC
membrane than NIgG and pooledhIgG. Immunofluorescence (IF) analysis also showed a
significant (*; p<0.05; n=6) colocalization of the M3-R and SScIgG binding to the human SMC
membranes, as determined by the secondary antibodies conjugated with TR and FITIC,
respectively (*; p<0.05; n=6; Fig. 3A,B). This colocalization was not observed with either
NIgG or pooledhIgG.
Functional Displacement of M3-Receptor (M3-R) Occupancy by SScIgG in Rat IAS
Smooth Muscle
These studies were carried out in the tonic component of the rat IAS smooth muscle
contraction induced by 10-4 M BeCh. As shown in Fig. 4A, 10-4 M BeCh caused an initial
phasic contraction followed by the sustained or tonic component. The sustained component
allowed sufficient time to examine different concentrations of NIgG, SScIgG or pooledhIgG
and darifenacin. As shown in Fig. 4A, only SScIgG significantly attenuated the tonic
component, because of the interference of M3-R occupancy by the SScIgGs as it resembled the
effect of darifenacin. Typical tracings of the effect of the functional occupancy and reversal of
the BeCh-induced M3-R activation by SScIgG and darifenacin are shown in Fig. 4B.
Assessment of SScIgG, NIgG and PooledhIgG Binding to M3-R using Western Blot
Analysis in Human IAS SMCs
Western blot analysis was used to confirm the binding of SScIgG to M3-R in HISMF, and
its reversal by pooledhIgG. When electrophoresed in parallel with the M3-R antibody, SScIgG
(and not NIgG and pooledhIgG) revealed a specific protein band coinciding with the M3-R in
HISMF (Fig. 5). The western blot analysis further showed that pretreatment of the SMC
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membranes with pooledhIgG added either 30 min before SScIgG, simultaneously or with the
premixed solution of SSCIgG with pooledhIgG (incubated at 37oC for 30 min) significantly
decreased binding of SScIgG with M3-R. A relative intensity graph was plotted by considering
the M3-R band intensity as 1.0. The Relative intensity of the SScIgG band was significantly
higher (0.57 ± 0.04; *; p<0.05) than with NIgG and pooledhIgG (0.03 ± 0.03 and 0.02 ± 0.04,
respectively).

SScIgG (5 µg/ml) combined with pooledhIgG displayed a significantly

decreased binding to the M3-R (from 0.57 ± 0.04 to 0.22 ± 0.04; *; p<0.05, n=6). Thus
collectively, these data show the presence of significant binding of SScIgG to the M3-R in the
human SMC membranes that is inhibited by pooledhIgG pretreatment.
Assessment of SScIgG, NIgG and PooledhIgG Binding to M3-R and Influence of
PooledhIgG employing Human IAS SMC Membrane Lysate and M3-R loop-2 Peptide
M3-R specific ELISA studies revealed a concentration-dependent increase in the binding
with the standard M3-R peptide and the HISMF (Fig. 6A), with the maximal binding at 300
pg/ml and 300 µg/ml, respectively. Following this, we used multiwell plates (used for ELISA)
preadsorbed with the maximal concentration (300 µg/ml) of the HISMF and performed ELISA
using different concentrations of the IgGs for M3-R binding analysis (Fig. 6B). The data
showed that SScIgG (and not NIgG and pooledhIgG) binds to HISMF significantly in a
concentration-dependent manner and the maximal OD at 5µg/ml of the lysate was 0.71 ± 0.05
(*; p<0.05; n=6). Pretreatment of the SScIgG with pooledhIgG (SScIgG+pooledhIgG) caused
a significant decrease in the binding of the SScIgG to the M3-R as reflected by a decrease in the
OD (from 0.71 ± 0.05 to 0.43 ± 0.024; *; p<0.05; n=6; Fig. 6B). These data suggest that the
membranes have M3-R domains that selectively bind with the SScIgGs.
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To further confirm these observations, we used multiwell plates (used for ELISA)
preadsorbed with the maximum concentration of M3-R second loop peptide (M3-RL2; 5µg/ml),
followed by the different concentrations of the IgGs. The data show a concentration-dependent
increase in M3-R binding with SScIgG (*; p<0.05; Fig. 6C) and not with NIgG or pooledhIgG
(p>0.05). However, pretreatment with pooledhIgG (SScIgG+pooledhIgG), caused a significant
decrease in the binding of the SScIgG to the M3-R (*; p<0.05). In contrast when M3-RL2
peptide was replaced with the M3-R third loop peptide (M3-RL3), there was no significant
binding (data not shown).

These data validate the results obtained with the intact cell

membrane studies, and suggest that SScIgGs display significant and specific binding to the M3R in the IAS SMC and further confirm a significant attenuation of this binding by pooledhIgG.
PooledhIgG Neutralizes the SScIGs in vitro: Studies using Human IAS SMC Membrane
Extracts
In these experiments, we determined the maximal OD following incubation of 5 µg/ml of
SScIgGs from different patients in multiwell plates (used for ELISA) preadsorbed with 400
pg/ml of M3-RL2 (Fig. 7). Pretreatment with pooledhIgG caused a significant and
concentration-dependent decrease in this maximal OD; 15 µg/ml of pooledhIgG decreased the
OD from 0.77 ± 0.34 to 0.41 ± 0.05 (*; p<0.05; n=6; Fig. 7A). However, inactivated
pooledhIgG failed to cause any decrease in the interaction between SScIgG and M3-RL2.
Interestingly, similar data were obtained when HISMF (400 mg/ml; Fig. 7B) instead of M3RL2 was used. Thus, these data show that neutralization of the SScIgG with pooledhIgG
causes a decrease in the M3-R binding by the SScIgGs.

Discussion
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Firstly, sera from patients with SSc

contain antibodies of the IgG class that act both at the myenteric nerves and at the smooth
muscle cell membrane receptors. Secondly, these antibodies reversibly block cholinergic nerve
and muscle functions. Thirdly, the effects of these antibodies can be inhibited by pooledhIgG.
Finally, the studies show that one of the prominent sites of action of these antibodies is at M3-R
and that this interaction can be effectively reversed by pooledhIgG. The proposed model of the
pathophysiological actions of SScIgGs and their reversal by pooledhIgG (via neutralization of
SScIgGs) in the gastrointestinal tract are given in Fig. 7.
The exact pathogenesis of GI dysmotility in SSc remains elusive. SSc patients are known to
harbor various anti-nuclear antibodies including anti-DNA-topoisomerase I (anti-topo I), anticentromere (CENPs-A, -B, -C and -D), and anti-RNA-polymerase III antibodies.1 Although,
the specific nature of antibodies present in the sera of GI symptomatic SSc patients antibodies
that may recognize epitopes present in the GI tract is not known, earlier studies from mouse
colon smooth muscle9 and rat IAS SMCs10 suggested these antibodies interfere with M3-R
activation.
The present studies provide evidence in favor of cholinergic blockade by M3-R inactivation
at the neural as well as at the muscular levels and show that SScIgGs cause significant
impairment of cholinergic contraction of the colon.

Importantly, these SScIgG-impaired

responses are significantly and selectively reversed by pooledhIgG. An effect of SScIgGs on
the cholinergic myenteric neurons was demonstrated by the significant decrease in the actual
release of ACh in these preparations, which is reversible by pooledhIgG.
Evidence for the partial effects of the SScIgGs at the myogenic level comes firstly from
studies showing that the SScIgGs (and not NIgGs and pooledhIgG) attenuate the IAS SMC
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contractility caused by BeCh-induced M3-R activation, while SScIgGs do not modify SMC
contraction by other agonists. Secondly, IF studies in the SMCs show that SScIgGs colocalize
with M3-R. Thirdly, the binding of M3-R by the SScIgGs is further evident by the WB studies
where SMC membranes incubated with the SScIgGs reveal a M3-R-specific band. Fourthly, the
binding of SScIgGs and interference with M3-R by SScIgGs is further evident from the
functional displacement of M3-R occupancy. Herein, SScIgGs (and not NIgGs) inhibit BeChinduced sustained contraction of intact IAS smooth muscle of rat in a concentration-dependent
manner. Finally, HISMF causes concentration-dependent increase in the M3-R binding when
multiwell plates (used for ELISA) are preadsorbed with M3-R-specific antibody. In addition,
SScIgGs cause selective and concentration-dependent increase in the binding when multiwell
plates pre-adsorbed with either HISMF or M3-RL2 are used. The studies reveal that M3-RL2 is
critical for the binding of the SScIgGs to the M3-R as the substitution of M3-RL2 with M3-RL3
produces no significant binding. Studies by Scarselli et al.27 corroborate these findings for the
critical role of M3-RL2 in the M3-R activation.
Thus, the results described here provide novel information demonstrating that the M3-R
inactivation caused by SScIgGs is reversible by pooledhIgG, via interference with the M3-R
occupancy. Pretreatment of SScIgGs with pooledhIgG significantly decreases the binding of
SScIgGs to purified M3-R peptide. This suggests the presence of anti-idiotypic antibodies in
pooledhIgG that block the pathophysiological activity of anti-M3-R antibodies in SScIgGs.
Functional displacement of M3-R occupancy by pooledhIgG is indicated by its ability to
reverse the SScIgGs-induced inhibition of BeCh-induced sustained contraction of intact IAS
smooth muscle. ELISA studies confirm that pooledhIgG reverses the SScIgGs-induced
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decrease in the binding with purified M3-R. Such data are similar whether multiwell plates are
preadsorbed with the HISMF or the M3-RL2 peptide.
Several possible mechanisms may explain the reversal of SScIgGs-induced M3-R
inactivation by pooledhIgG including neutralization,28,29 desensitization, internalization or
degradation of the IgGs.30-32
Present studies provide further evidence that pooledhIgG reverses M3-R inactivation
whether the cells are incubated with pooledhIgG followed by SScIgG or with the premixed
SScIgGs and pooledhIgG. This is shown by IF, WB, ELISA, neutralization, and functional
displacement of M3-R occupancy studies. Therefore we suggest that the effects of pooledhIgG
occur primarily by binding with the SScIgG thus neutralizing the effects of these antibodies in
the circulation. This hypothesis is further supported by the observations that pooledhIgG forms
an immune complex with IgGs interacting with Fcγ receptors on dendritic cells thus reducing
the severity of autoimmune diseases12,33 From the present data, we postulate that neutralization
of these pathogenic antibodies by pooledhIgG may represent a novel approach for the
treatment of SSc GI motility disorders by blocking cholinergic dysfunction induced by
SScIgG. However, the exact mechanism, and the role of other pathways including possible
removal of the SSc pathogenic antibodies in the therapeutic efficiency and efficacy of
pooledhIgG remain to be determined. Previously reported studies on the effect of pooledhIgG
in SSc patients11 have primarily focused on cutaneous and articular manifestations. Therefore,
the present studies that identify a novel therapeutic and potentially mechanistic role of
pooledhIgG in the GI dysfunction of SSc may represent a major step forward for the treatment
of SSc.
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In summary, the present studies provide evidence for the proposed mechanism for the M3-Rmediated cholinergic dysfunction in SSc-related GI manifestations and its restoration by
pooledhIgG.

Collectively, we posit that neutralization of these pathogenic antibodies by

pooledhIgG may in part relieve SSc-associated GI motility disorders by blocking cholinergic
inhibition. Based on the long-term use of pooledhIgG in other autoimmune diseases, we suggest
that pooledhIgG may provide a novel and safe therapy for the SSc-related GI motility disorders.
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Figure Legends
Fig. 1. A. TTX, atropine, and darifenacin significantly attenuate the EFS-induced contraction of
the rat colonic smooth muscle caused by EFS (*; p<0.05; n=6). SScIgG also causes significant
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(*; p<0.05; n=6) attenuation of these EFS responses that is reversed by pooledhIgG to values
not significantly different from those obtained in the control and the pooledhIgG alone
experiments (p>0.05). B. EFS causes a significant (*; p<0.05; n=4) increase in ACh release that
is significantly (**; p<0.05; n=4) mitigated not only by 0Ca2+ and TTX but also by SScIgG.
The effects of SScIgG are reversed by pooledhIgG pre-treatment. C. SScIgG significantly (*;
p<0.05; n=6) inhibits M3-R activation-induced human SMC contraction by BeCh. These
inhibitor effects of SScIgG are restored by pooledhIgG in a concentration-dependent manner
(significantly by 1mg/ml pooledhIgG; *), and almost completely by 10 mg/ml pooledhIgG to
the levels that are not significantly different from control, NIG and pooledhIgG experiments
(p>0.05).
Fig. 2. A. Time-dependent increase in the M3-R-specifiic IF intensity (IFI) in human IAS SMCs
following treatment with (1:200 or 5 µg/ml) of M3-R antibody. B. Maximal IFI of human IAS
SMC occurs following 20 min of incubation with the M3-R antibody. C. M3-R occupancy with
SScIgG in the SMC membrane is significantly higher (*; p<0.05) as compared with NIgG and
pooledhIgG, as determined by IFI/unit area. D. An example of data collection for the
intensity/unit area on the membrane. E. Quantitative data showing % maximal IFI/unit area
with NIgG, SScIgG, pooledhIgG (on the basis of 100% for M3-R antibody).
Fig. 3. A. A. Immunocytochemical colocalization of different IgG preparations (SScIgG, a;
NIgG, b; and pooledhIgG, c; (all FITC-conjugated; green)) and M3-R (TR-conjugated; red) and
nucleus is stained blue with DAPI. Line graph analyses for the localization of these IgGs on the
SMC membrane and their corresponding colocalization with M3-R are shown on the extreme
right of each IgG plate. (B) Bar graph data show significant colocalization of SScIgG (vs. NIgG
and pooledhIgG) with the M3-R at the SMC membrane.
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Fig. 4. A. In control experiments M3-R activation by BeCh causes a two phase contraction of
the IAS; phasic followed by the tonic. SScIgG (but not NIgG and pooledhIgG) in resemblance
with darifenacin (M3-R selective inhibitor) causes significant and concentration-dependent
decrease in the BeCh-induced sustained contraction (*; p<0.05; n=6). B. Actual tracings of the
effect of darifenacin, SScIgG, NIgG, and pooledhIgG on the BeCh-induced sustained
contraction of the IAS.
Fig. 5. Western blot analysis shows significant (*; p<0.05, n=6) binding of SScIgG with M3-R
(p<0.05) in contrast with the other IgGs, in human IAS SMC membrane fractions (HISMF). In
addition, combination of pooledhIgG+SScIgG causes significant decrease in this binding (*; p
<0.05; n=6).
Fig. 6. A. ELISA binding studies for M3-R peptide and human IAS SMC membrane fraction
(HISMF). A. OD concentration-curves using M3-R standards and HISMF. B. Data show that
M3-R antibody and SScIgG bind with HISMF in a concentration-dependent manner (*; p<0.05;
n=6), and pooledhIgG significantly decreases this binding. C. Similar data were obtained when
M3-R peptide (M3-RL2) instead of HISMF is used.
Fig. 7. A. Neutralization studies via ELISA show that pooledhIgG (active and not inactivated
pooledhIgG) causes significant and concentration-dependent decrease (*; p<0.05) in the
binding of SScIgG at the M3-RL2. B. Similar data were obtained when M3-RL2 was replaced
with the membrane lysates. In these experiments, maximal OD is first observed following the
incubation of 400 µg of HISMF with 5 µg/ml of SScIgGs. C. A working model suggests that
SScIgGs lead to gastrointestinal motility dysfunction by blocking M3-R at the cholinergic
neurotransmission at the neural and the SMC levels. Data further suggest that pooledhIgG
neutralizes the SSc autoantibodies in the circulation thus attenuating these effects of SScIgGs
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on M3-R inhibition. This neutralization may in part reverse the pathophysiology of SSC
gastrointestinal smooth muscle dysfunction.
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